ライフサイエンスコーパス: lipoplex

1 mple ionic complexes with the nucleic acids (lipoplexes).

2 molecules came into close association in the lipoplex.

3 influences the biological properties of the lipoplex.

4 the excess component was separated from the lipoplex.

5 on the type of PEG conjugate employed in the lipoplex.

6 g normal saline, liposomes alone, or control lipoplexes.

7 on in the liver of mice injected with EC-SOD lipoplexes.

8 the rate of fusion of anionic liposomes with lipoplexes.

9 of only approximately 2 is determined in SUV lipoplexes.

10 hate was found to be unique in its effect on lipoplexes.

11 es, HXBDeltaBgl or pNL4-3, using transferrin-lipoplexes.

12 eraction or the cell up-take of the cationic lipoplexes.

13 nsertion of 2 or 5 kDa PEG-DSPE on preformed lipoplexes.

14 om fetal calf serum that are associated with lipoplexes.

15 ng of viral/exosomal RNAs and MBs within the lipoplexes.

16 anism underlying efficient DNA transfer from lipoplexes.

17 ead groups and caused the aggregation of the lipoplexes.

18 drugs reduced the gene silencing activity of Lipoplex, a complex of small interfering RNA (siRNA) and

19 umor-bearing mice via a tail vein, and these lipoplexes accumulated sufficiently in both angiogenic v

20 n and enhanced membrane fluidity in both the lipoplex and cellular membranes.

21 rties of a lipopolyplex formulation with its lipoplex and polyplex equivalents to assess the role of

22 ding and endocytosis of fluorescence-labeled Lipoplex and the amount of siRNA at its site of action R

23 RNA that has no mRNA targets, from its PCat lipoplex and/or endosomes/lysosomes.

24 and depends on the lipid composition of both lipoplexes and anionic liposomes.

25 ranges from small cationic lipids applied in lipoplexes and lipid nanoparticles, over medium-sized se

26 opolyplexes combined the optimal features of lipoplexes and polyplexes showing optimal cell uptake, e

27 ith previous finding for the role of DOPE in lipoplexes and support the hypothesis regarding the func

28 importance of the lipid composition of both lipoplexes and target membranes and suggests optimal tra

29 dynamic interactions between polyanions and Lipoplex, and the use of QP modeling to delineate the co

30 m a foundation for the future use of topical lipoplex applications to alter hair follicle phenotype a

31 Although siRNA lipoplexes are easily formulated, several of the most ef

32 the protein corona that occur as DOTAP-based lipoplexes are formulated with different amounts of chol

33 i) differences in the extents to which these lipoplexes are internalized by cells and (ii) changes in

34 Thus, C18:1/C10-EPC lipoplexes are likely to easily fuse with membranes, and

35 Several studies have demonstrated that lipoplexes are two-phase systems over most mixing lipid/

36 We have developed lipoplexes as a versatile nanoparticle carrier system fo

37 sed the same pegylated cationic (PCat)-siRNA lipoplexes as in the intraperitoneal study to treat mice

38 er show that the composition and size of the lipoplex, as well as the lipid composition of the endoso

39 utogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immuno

40 Initial results indicated that lipoplexes, but not polyplexes based on polyethylenimine

41 vironment (i.e., prior to internalization of lipoplexes by cells).

42 Characterization of lipoplexes by small-angle neutron scattering (SANS) and

43 s, we hypothesize that virus-like particles (lipoplexes) can be utilized to initiate an anti-viral in

44 e glycol (PEG) to prepare APRPG-PEG-modified lipoplexes carrying miR-499 (APRPG-miR-499).

45 The encapsulation efficiency of the CD-lipoplex complexes were also studied with and without th

46 Among the nonviral vectors, the lipoplexes (complexes of cationic liposome/pDNA) are the

47 discovery of the transfection properties of lipoplexes composed of positively charged cationic lipid

48 xidized BFDMA with ascorbic acid resulted in lipoplexes composed of reduced BFDMA, as characterized b

49 al transfection may be obtained by tailoring lipoplex composition to the lipid composition of target

50 Cationic lipid-nucleic acid complexes (lipoplexes) consisting of dioleoyltrimethylammoniumpropa

51 cacious at endosomal escape than traditional lipoplex constructs.

52 X-ray diffraction studies suggest that lipoplexes containing analogue 4 display increased stabi

53 8h after treatment with anti-SP-C-conjugated lipoplexes containing the test microRNA miR-486, express

54 nce of cells by addition of ascorbic acid to lipoplex-containing media in which cells are growing.

55 plex (PCL) platform consisting of a cationic lipoplex core and a biocompatible, pH-responsive polymer

56 xing lipid affects uptake and translation of lipoplex-delivered RNA in resident cells in human skin e

57 ignificant mRNA transfection was achieved by lipoplex delivery in quiescent (passage 0) human umbilic

58 ity to develop a deeper understanding of DNA lipoplex delivery through the cell.

59 Second, both caused Lipoplex destabilization to release double- and single-s

60 Products of Lipoplex destabilization were separated, identified, and

61 t differences in the nanostructures of these lipoplexes (determined by cryo-TEM) and their zeta poten

62 cell surface binding and internalization of Lipoplex, diminished the siRNA concentration in RISC, an

63 ing free energy was determined by monitoring lipoplex dissociation under conditions of increasing sal

64 at carboxymethyl-beta-cyclodextrin increased lipoplexes' encapsulation efficiency using both NanoAsse

65 se findings indicate that ATII cell-targeted lipoplexes exhibit all the desired characteristics of an

66 lead analogue DS(14-yne)TAP (4):cholesterol lipoplexes exhibits double the transfection level with l

67 Lipoplex/virus or lipoplex/exosome fusion leads to the mixing of viral/exo

68 The exception was DOTAP:DOPE-containing lipoplex for which the enthalpy of formation was exother

69 The use of lipoplexes for the intracellular delivery of nucleic aci

70 ifferences of the liposomes used, a model of lipoplex formation is proposed.

71 DNA lipoplexes formed from DNA with a range of 21 bp to 5.5

72 nanostructures, properties, and behaviors of lipoplexes formed using BFDMA and macromolecular plasmid

73 quence-specific gene silencing in cells, but lipoplexes formed using oxidized BFDMA do not.

74 cal properties and control the activities of lipoplexes formed using siRNA-based constructs.

75 The level of cell transfection mediated by lipoplexes formed using the ferrocenyl lipid bis(11-ferr

76 is possible to chemically transform inactive lipoplexes (formed using oxidized BFMDA) to "active" lip

77 Specifically, the accessible pDNA in lipoplexes formulated with cytofectins containing a gamm

78 ion over the course of 72 h, irrespective of lipoplex formulation.

79 or selecting possible "helper" lipids in the lipoplex formulations, and in searches for correlations

80 ee siRNA or siRNA-loaded non-acid-degradable lipoplex formulations, respectively.

81 ivo delivery of naked plasmid DNA (pDNA) and lipoplex formulations.

82 ce the biological activity of naked pDNA and lipoplex formulations.

83 elease of transfection-competent siRNA-DOTAP lipoplexes from the LPNs.

84 n contrast, the separated negatively charged lipoplexes had a prominent internal 5.9 +/- 0.1-nm perio

85 In the present study, lipoplexes having the identical lipid composition were f

86 on and dispersion of nanoparticles and siRNA-lipoplexes in 3-dimensional tumor histocultures, and pro

87 nt, composition, and structure of individual lipoplexes in a population evolve over time, starting at

88 usogenicity and membrane permeation of their lipoplexes in endosomes via the formation of inverted he

89 The main hurdle to using lipoplexes in gene therapy lies in their immunostimulato

90 roparticle-based transfection of plasmid DNA lipoplexes in several primary human cell types.

91 carcinoma cells were transfected with these lipoplexes in vitro.

92 er the nanostructures and behaviors of siRNA lipoplexes in ways not possible using conventional lipid

93 lasmid accumulation in tumors as compared to lipoplexes in which the ligand was excluded from the dom

94 Lipoplexes induced no weight loss, hypoxemia, lung dysfu

95 ed mRNA efficiently at 4 and 24 h after mRNA-lipoplex injection and contributed the greatest proporti

96 ulation when injection occurred 24 h after a lipoplex injection.

97 he kinds of lipid phases that may arise when lipoplexes interact with cellular lipids during DNA tran

98 DNA release from lipoplexes is an essential step during lipofection and i

99 t and relatively safe DNA transfection using lipoplexes makes them an appealing alternative to be exp

100 and co-lipid combinations currently used for lipoplex-mediated gene delivery reflects the fact that t

101 ent a novel assay by which tethered cationic lipoplex nanoparticles containing molecular beacons (MBs

102 Cationic lipoplex nanoparticles linked onto the surface of a thin

103 vaccine with backbone-optimized uridine mRNA-lipoplex nanoparticles) and modified (m) FOLFIRINOX (che

104 zed neoantigen vaccine based on uridine mRNA-lipoplex nanoparticles, we synthesized mRNA neoantigen v

105 Adjuvant mRNA-lipoplex neoantigen vaccines may thus solve a pivotal ob

106 We measured the stoichiometry of the lipoplex, noted its colloidal properties, and observed i

107 Non decorated or OCE-decorated lipoplexes (OCE(free)-LPX and OCE-LPX, respectively) wer

108 Lipoplexes of oxidized BFDMA can be activated in situ to

109 Treatment of lipoplexes of oxidized BFDMA with ascorbic acid resulted

110 es and aspects of redox control observed for lipoplexes of plasmid DNA are maintained in complexes fo

111 Specifically, lipoplexes of siRNA and reduced BFDMA lead to high level

112 Lipoplexes of the optimal formulation were relatively mo

113 Lipid/DNA lipoplexes, on the other hand, produced aggregated masse

114 re efficient transfection agents than binary lipoplex or polyplex formulations.

115 d cytosolic release of siRNAs, formulated in lipoplexes or lipid nanoparticles, by live-cell imaging

116 r chemical structure and virtually identical lipoplex organization.

117 An acid-degradable polymer-caged lipoplex (PCL) platform consisting of a cationic lipople

118 PEG and OCE/PEG decorated lipoplexes (PEG-OCE(free)-LPX and PEG-OCE-LPX, respectiv

119 ct of ligand microenvironment by utilizing a lipoplex possessing a cholesterol domain.

120 Lipoplexes prepared at a threefold or greater excess of

121 r by characterizing the assembly of cationic lipoplexes prepared from 1-[2-(oleoyloxy)ethyl]-2-oleyl-

122 ds to the nucleic acid effectively and whose lipoplexes promote long-lasting inhibition, have high bi

123 First, these agents altered several Lipoplex properties (i.e., reduced particle size, change

124 This may be due to the greater ability of lipoplexes relative to polyplexes to promote endosomal e

125 It is likely that these two lipoplexes represent structures with different lipid and

126 ximately 4.5 and 9 are found in LUV and sMLV lipoplexes, respectively, a final (+/-) ratio of only ap

127 e shown that gene silencing assays employing lipoplexes result in a high rate of false negatives (~90

128 The negatively charged lipoplex showed increased transfection activity compared

129 nd cytotoxicity, while it did not affect the lipoplex size and ON loading.

130 ion reduced the zeta potential, enhanced the lipoplex stability in serum and decreased both hemolysis

131 d were examined to determine their effect on lipoplex structure and biological activity.

132 While many studies have demonstrated that lipoplex structure and function can be dramatically comp

133 ns, and in searches for correlations between lipoplex structure and transfection activity.

134 The macroscopic lipoplex structure was assessed using a dye-binding assa

135 y and measurements of the zeta potentials of lipoplexes suggested that these large differences in cel

136 ranasally-administered, anti-SP-C-conjugated lipoplexes targeted mouse ATII cells with >70% specifici

137 izing protein expression, using modular mRNA lipoplexes that are more compatible with product develop

138 the introduction of lipid nanoparticles and lipoplexes that can effectively deliver mRNA vaccines, i

139 lar vesicles (sMLV), as opposed to SUV, form lipoplexes that exist as a single phase over a relativel

140 Lipoplexes that included the ligand within the cholester

141 es (formed using oxidized BFMDA) to "active" lipoplexes that mediate high levels of transfection by t

142 vis spectrophotometry, and lead to activated lipoplexes that mediated high levels of transgene expres

143 methods (e.g. RNA conjugates, polymers, and lipoplexes) that enhance cellular uptake of RNA therapeu

144 In lipoplexes, the lipid membranes as observed in freeze-fr

145 esign parameters for effective permeation of lipoplexes through the skin layers and deposition at the

146 exceptional pH-sensitivity and triggered its lipoplex to permeate model biomembranes within the time

147 The ability of the formulated lipoplexes to internalize into melanoma cells, knockdown

148 cal administration of liposome-DNA mixtures (lipoplex) to mouse skin and to human skin xenografts res

149 akes use of DNA/cationic liposome complexes (lipoplexes) to deliver the genetic material.

150 A comprehensive model of DNA lipoplex trafficking through live cells has yet to be de

151 that there was less cell death in the EC-SOD lipoplex-treated group.

152 erum superoxide dismutase activity in EC-SOD lipoplex-treated mice was higher than in the control gro

153 elivery and transfection efficiency of siRNA-lipoplexes under the locoregional setting in vivo (i.e.,

154 M) revealed changes in the nanostructures of lipoplexes upon the addition of ascorbic acid, from aggr

155 act spontaneously with nucleic acids to form lipoplexes used for gene delivery.

156 Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoan

157 Lipoplex/virus or lipoplex/exosome fusion leads to the m

158 contrast, transfection activity of different lipoplexes was cell type and vehicle dependent and did n

159 ion of 53.7 nM, and the performance of these lipoplexes was not impeded by serum.

160 cial lipid-based transfection reagent (siRNA lipoplex) was less functional following microneedle coat

161 the vehicle and cytofectin components of the lipoplex were uncovered, they did not extrapolate to tre

162 Relevant physical properties of the lipoplexes were also examined; specifically, membrane fu

163 nary localization and ATII cell specificity, lipoplexes were conjugated to an antibody directed again

164 Lipoplexes were formed by mixing cholesterol-grafted miR

165 Lipoplexes were formulated in three different vehicles c

166 Lipoplexes were formulated using two injection vehicles

167 e receiving portal vein injections of EC-SOD lipoplexes were much lower than in those receiving norma

168 The colloidal properties of the lipoplexes were principally determined by the cationic l

169 ysical properties and biological activity of lipoplexes were systematically examined.

170 when cationic lipid-nucleic acid complexes (lipoplexes) were formulated at a nitrogen:phosphorothioa

171 nt, which dictate the structure of resulting lipoplex (whether lamellar complex or DNA-coated vesicle

172 re consistent with structural changes in the lipoplex, which correlated with alterations in the formu

173 riably associated with administration of the lipoplexes, which must be avoided in the clinical applic

174 Our computational fusion experiments of lipoplexes with endosomal membrane models show two disti

175 We prepared formulations of lipoplexes with ionizable, cationic or zwitterionic lipi

176 amphiphilic nature of reduced BFDMA leads to lipoplexes with physical properties resembling those for

177 The OCE decoration yielded lipoplexes with size of about 240 nm, 84% loading effici

178 a small library of liposome-siRNA complexes (lipoplexes) with different physicochemical properties.